You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

Feb 02, 2021

Evive Biotech Announces First Patient Dosed in Phase 2 Study to Evaluate the Efficacy and Safety of F-652 in Patients with Moderate to Severe COVID-19

  • Evive’s phase 2 study is being conducted in partnership with Tulane University, New Orleans
  • Study plans to include four cohorts with a total of 38 patients across approximately 10 sites in the US and Russia.

Feb 2, 2021, Singapore – Evive Biotech (Evive), an innovative global biopharmaceutical company developing novel biological therapeutics, announced today that it has dosed the first patient in its Phase 2, randomized, double-blind, placebo-controlled, dose-escalation, multicenter study to evaluate the efficacy and safety of F-652 (IL-22:IgG2 Fusion Protein) in patients with moderate to severe COVID-19.

The study anticipates enrolling four cohorts with a total of 38 patients across approximately 10 facilities in the US and Russia, with the first clinical readout expected by end of 2021. Eligible patients will be aged 18 years or older with a COVID-19 diagnosis confirmed by a positive, polymerase chain reaction (PCR) test.

Dr. William Daley, Chief Medical Officer of Evive Biotech commented, “As COVID-19 continues to spread across the world, there is a significant need to develop effective treatment options for patients. The dosing of the first patient with Evive Biotech’s F-652 treatment represents a significant milestone in the journey to offering a promising therapeutic candidate to treat patients with modest to severe COVID-19 symptoms.”

“We are eager to explore the role that F-652 can play for the treatment of COVID-19,” said Professor of Medicine and Pediatrics, the John W Deming Endowed Chair in Internal Medicine and Director, Tulane School of Medicine, Dr. Jay Kolls. He added, “Administration of F-652 following influenza infection has been shown to reduce fluid buildup and inflammation, and showed decreased lung, liver, and spleen bacterial burdens post-infection in a murine pneumonia model. Taken together, F-652 has the potential to be effective in promoting a protective response in the lungs following infection with COVID-19.”

***ENDS***

 

Notes for editors

For further information, please contact:

Brunswick Group

evive.biotech@brunswickgroup.com

+65 6426 8188

About F-652

F-652 is a novel dimeric IL-22 fusion protein currently in multiple development programs to treat inflammatory diseases. IL-22 has been shown to have natural growth-promoting activity in epithelial cells to combat organ injuries induced by a variety of causes and eventual fatal organ failures.  Published literature and Evive’s completed clinical trials have presented F-652 with opportunities to treat multiple diseases, some of which Evive is actively pursuing or developing, including acute graft vs. host disease (GvHD) and acute alcoholic hepatitis.  F-652 has been postulated as a potential therapeutic candidate for the treatment of patients with COVID-19, particularly in patients with moderate to severe symptoms.

About Evive Biotech

Evive Biotech is a global biologics company with Asian roots, developing a portfolio of novel biological therapies for patients and healthcare professionals worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology and inflammatory disorders. Founded in 2004, we have over 200 employees today with operations in the US, Singapore and China. We adopt a holistic approach to drug development, combining exceptional research and commercialization capabilities with world class in-house regulatory expertise to bring innovative therapies to market quickly and efficiently. Our state-of-the-art in-house cGMP facility allows us to manufacture at commercial scale in accordance with FDA, EMA and NMPA standards and industry best practices. Through partnerships with industry, physicians, and regulatory authorities, we develop revolutionary remedies that we believe will make a real and lasting difference to patients and their families worldwide.

Evive Biotech was previously known as Generon. To learn more, visit evivebiotech.com.

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

X
Share to WeChat